Member access

4-Traders Homepage  >  Shares  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

MORPHOSYS AG (MOR)

27
Real-time Quote. Real-time Tradegate - 10/31 03:23:15 pm
75.994 EUR   +0.01%
1d ago MORPHOSYS : to Host Q3 2014 Conference Call on 07 November 2014
1d ago MORPHOSYS : to Host Q3 2014 Conference Call on 07 November 2014
10/23 MORPHOSYS : Updates its 2014 Financial Guidance
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra
10/27/2014 10/28/2014 10/29/2014 10/30/2014 10/31/2014 Date
72.36(c) 72.25(c) 72.45(c) 75.99(c) 75.73 Last
91 376 73 040 51 829 157 225 94 570 Volume
-0.69% -0.15% +0.28% +4.89% -0.34% Change
More quotes
Company
MorphoSys AG is engaged in the development of antibodies for therapeutic, diagnostic, and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development, and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
Surperformance© rating of MorphoSys AG
Trading Rating : Investor Rating :
More about the company
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Financials (€)
Sales 2014 62,6 M
EBIT 2014 -13,9 M
Net income 2014 -12,2 M
Finance 2014 276 M
Yield 2014 -
Sales 2015 67,2 M
EBIT 2015 -9,54 M
Net income 2015 -7,10 M
Finance 2015 254 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 27,6x
EV / Sales 2015 26,0x
Capitalization 2 004 M
More Financials
Latest news on MORPHOSYS AG
1d ago MORPHOSYS : to Host Q3 2014 Conference Call on 07 November 2014
1d ago MORPHOSYS : to Host Q3 2014 Conference Call on 07 November 2014
2d ago MORPHOSYS : Updates Its 2014 Financial Guidance
10/23 MORPHOSYS : Updates its 2014 Financial Guidance
10/23 MORPHOSYS : Updates its 2014 Financial Guidance (Adhoc)
10/22 MORPHOSYS : Ad hoc: MorphoSys Updates its 2014 Financial Guidance
10/22 MORPHOSYS : Updates its 2014 Financial Guidance (Ad hoc)
10/22 MORPHOSYS : to Receive Milestone Payment for Guselkumab Phase 3 Program
10/22 MORPHOSYS : to Receive Milestone Payment for Guselkumab Phase 3 Program
10/20 MORPHOSYS : Announces Clinical Milestone in Ophthalmology Program
10/20 MORPHOSYS : Announces Clinical Milestone in Ophthalmology Program
10/15 MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF